Related references
Note: Only part of the references are listed.ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
S. Pospisilova et al.
LEUKEMIA (2012)
Mutational Status of the TP53 Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
David Gonzalez et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Bendamustine Combined With Rituximab in Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia: A Multicenter Phase II Trial of the German Chronic Lymphocytic Leukemia Study Group
Kirsten Fischer et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Moving from prognostic to predictive factors in chronic lymphocytic leukaemia (CLL)
Thorsten Zenz et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2010)
microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia
Daniela Asslaber et al.
BLOOD (2010)
microRNA fingerprinting of CLL patients with chromosome 17p deletion identify a miR-21 score that stratifies early survival
Simona Rossi et al.
BLOOD (2010)
Interdependent regulation of p53 and miR-34a in chronic lymphocytic leukemia
Olaf Merkel et al.
CELL CYCLE (2010)
MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia
Kerstin Willander et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
MUT-TP53 2.0: A Novel Versatile Matrix for Statistical Analysis of TP53 Mutations in Human Cancer
Thierry Soussi et al.
HUMAN MUTATION (2010)
Rituximab Plus Fludarabine and Cyclophosphamide Prolongs Progression-Free Survival Compared With Fludarabine and Cyclophosphamide Alone in Previously Treated Chronic Lymphocytic Leukemia
Tadeusz Robak et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TP53 Mutation and Survival in Chronic Lymphocytic Leukemia
Thorsten Zenz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
TP53 mutation profile in chronic lymphocytic leukemia: evidence for a disease specific profile from a comprehensive analysis of 268 mutations
T. Zenz et al.
LEUKEMIA (2010)
A map of human genome variation from population-scale sequencing
David Altshuler et al.
NATURE (2010)
Monoallelic and biallelic inactivation of TP53 gene in chronic lymphocytic leukemia: selection, impact on survival, and response to DNA damage
Jitka Malcikova et al.
BLOOD (2009)
Detailed analysis of p53 pathway defects in fludarabine-refractory chronic lymphocytic leukemia (CLL): dissecting the contribution of 17p deletion, TP53 mutation, p53-p21 dysfunction, and miR34a in a prospective clinical trial
Thorsten Zenz et al.
BLOOD (2009)
De novo deletion 17p13.1 chronic lymphocytic leukemia shows significant clinical heterogeneity: the M. D. Anderson and Mayo Clinic experience
Constantine S. Tam et al.
BLOOD (2009)
miR-34a as part of the resistance network in chronic lymphocytic leukemia
Thorsten Zenz et al.
BLOOD (2009)
The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
Davide Rossi et al.
CLINICAL CANCER RESEARCH (2009)
Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
Stephan Stilgenbauer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
The detection of TP53 mutations in chronic lymphocytic leukemia independently predicts rapid disease progression and is highly correlated with a complex aberrant karyotype
F. Dicker et al.
LEUKEMIA (2009)
17p13/TP53 deletion in B-CLL patients is associated with microRNA-34a downregulation
M. K. Dijkstra et al.
LEUKEMIA (2009)
miR-34a, miR-29c and miR-17-5p are downregulated in CLL patients with TP53 abnormalities
M. Mraz et al.
LEUKEMIA (2009)
Monoallelic TP53 inactivation is associated with poor prognosis in chronic lymphocytic leukemia:: results from a detailed genetic characterization with long-term follow-up
Thorsten Zenz et al.
BLOOD (2008)
Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer
Dmitri Lodygin et al.
CELL CYCLE (2008)
MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia
Irina Gryshchenko et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial
D. Catovsky et al.
LANCET (2007)
Aristolochic acid and the etiology of endemic (Balkan) nephropathy
Arthur P. Grollman et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells
C. Welch et al.
ONCOGENE (2007)
Differential regulation of microRNAs by p53 revealed by massively parallel Sequencing -: miR-34a is a p53 target that induces apoptosis and G1-arrest
Valery Tarasov et al.
CELL CYCLE (2007)
A microRNA component of the p53 tumour suppressor network
Lin He et al.
NATURE (2007)
Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis
Tsung-Cheng Chang et al.
MOLECULAR CELL (2007)
TP53 mutations in human cancers:: functional selection and impact on cancer prognosis and outcomes
A. Petitjean et al.
ONCOGENE (2007)
Inactive full-length p53 mutants lacking dominant wild-type p53 inhibition highlight loss of heterozygosity as an important aspect of p53 status in human cancers
Lawrence R. Dearth et al.
CARCINOGENESIS (2007)
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment
M Trbusek et al.
LEUKEMIA (2006)
Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions
G Lozanski et al.
BLOOD (2004)
A single nucleotide polymorphism in the MDM2 promoter attenuates the p53 tumor suppressor pathway and accelerates tumor formation in humans
GL Bond et al.
CELL (2004)
Understanding the function-structure and function-mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis
S Kato et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy
I Sturm et al.
CELL DEATH AND DIFFERENTIATION (2003)
Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: Report of the BIOMED-2 Concerted Action BMH4-CT98-3936
JJM van Dongen et al.
LEUKEMIA (2003)
Targeted point mutations of p53 lead to dominant-negative inhibition of wild-type p53 function
A de Vries et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Share Paper
